nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—Ergotamine—ADRA1D—polycystic ovary syndrome	0.00949	0.21	CrCbGaD
Dihydroergotamine—Bromocriptine—ADRA1D—polycystic ovary syndrome	0.00915	0.202	CrCbGaD
Dihydroergotamine—Rigors—Metformin—polycystic ovary syndrome	0.00864	0.067	CcSEcCtD
Dihydroergotamine—Ergotamine—ADRA1B—polycystic ovary syndrome	0.0081	0.179	CrCbGaD
Dihydroergotamine—Bromocriptine—ADRA1B—polycystic ovary syndrome	0.00781	0.173	CrCbGaD
Dihydroergotamine—Ear pain—Metformin—polycystic ovary syndrome	0.006	0.0465	CcSEcCtD
Dihydroergotamine—Injury—Metformin—polycystic ovary syndrome	0.00557	0.0432	CcSEcCtD
Dihydroergotamine—Ergotamine—ADRA1A—polycystic ovary syndrome	0.00545	0.12	CrCbGaD
Dihydroergotamine—Bromocriptine—ADRA1A—polycystic ovary syndrome	0.00526	0.116	CrCbGaD
Dihydroergotamine—Migraine—Metformin—polycystic ovary syndrome	0.00504	0.0391	CcSEcCtD
Dihydroergotamine—Cramp muscle—Metformin—polycystic ovary syndrome	0.00461	0.0358	CcSEcCtD
Dihydroergotamine—Angina pectoris—Metformin—polycystic ovary syndrome	0.00431	0.0334	CcSEcCtD
Dihydroergotamine—Sweating increased—Metformin—polycystic ovary syndrome	0.00431	0.0334	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00411	0.0319	CcSEcCtD
Dihydroergotamine—Rhinitis—Metformin—polycystic ovary syndrome	0.00355	0.0275	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00352	0.0273	CcSEcCtD
Dihydroergotamine—Flushing—Metformin—polycystic ovary syndrome	0.00329	0.0255	CcSEcCtD
Dihydroergotamine—Chills—Metformin—polycystic ovary syndrome	0.00318	0.0246	CcSEcCtD
Dihydroergotamine—Muscle spasms—Metformin—polycystic ovary syndrome	0.00296	0.023	CcSEcCtD
Dihydroergotamine—Tremor—Metformin—polycystic ovary syndrome	0.00289	0.0224	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00286	0.0222	CcSEcCtD
Dihydroergotamine—Malaise—Metformin—polycystic ovary syndrome	0.00278	0.0216	CcSEcCtD
Dihydroergotamine—Palpitations—Metformin—polycystic ovary syndrome	0.00272	0.0211	CcSEcCtD
Dihydroergotamine—Hypertension—Metformin—polycystic ovary syndrome	0.00266	0.0206	CcSEcCtD
Dihydroergotamine—Myalgia—Metformin—polycystic ovary syndrome	0.00262	0.0204	CcSEcCtD
Dihydroergotamine—Discomfort—Metformin—polycystic ovary syndrome	0.00259	0.0201	CcSEcCtD
Dihydroergotamine—Oedema—Metformin—polycystic ovary syndrome	0.00252	0.0195	CcSEcCtD
Dihydroergotamine—Shock—Metformin—polycystic ovary syndrome	0.00248	0.0192	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00243	0.0189	CcSEcCtD
Dihydroergotamine—Anorexia—Metformin—polycystic ovary syndrome	0.0024	0.0186	CcSEcCtD
Dihydroergotamine—Hypotension—Metformin—polycystic ovary syndrome	0.00235	0.0182	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00229	0.0178	CcSEcCtD
Dihydroergotamine—Paraesthesia—Metformin—polycystic ovary syndrome	0.00226	0.0175	CcSEcCtD
Dihydroergotamine—Dyspnoea—Metformin—polycystic ovary syndrome	0.00224	0.0174	CcSEcCtD
Dihydroergotamine—Somnolence—Metformin—polycystic ovary syndrome	0.00224	0.0173	CcSEcCtD
Dihydroergotamine—Dyspepsia—Metformin—polycystic ovary syndrome	0.00221	0.0172	CcSEcCtD
Dihydroergotamine—Decreased appetite—Metformin—polycystic ovary syndrome	0.00219	0.017	CcSEcCtD
Dihydroergotamine—Fatigue—Metformin—polycystic ovary syndrome	0.00217	0.0168	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00207	0.0161	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00206	0.016	CcSEcCtD
Dihydroergotamine—Urticaria—Metformin—polycystic ovary syndrome	0.002	0.0155	CcSEcCtD
Dihydroergotamine—Abdominal pain—Metformin—polycystic ovary syndrome	0.00199	0.0154	CcSEcCtD
Dihydroergotamine—Asthenia—Metformin—polycystic ovary syndrome	0.00181	0.014	CcSEcCtD
Dihydroergotamine—Pruritus—Metformin—polycystic ovary syndrome	0.00178	0.0138	CcSEcCtD
Dihydroergotamine—Diarrhoea—Metformin—polycystic ovary syndrome	0.00172	0.0134	CcSEcCtD
Dihydroergotamine—Dizziness—Metformin—polycystic ovary syndrome	0.00166	0.0129	CcSEcCtD
Dihydroergotamine—Vomiting—Metformin—polycystic ovary syndrome	0.0016	0.0124	CcSEcCtD
Dihydroergotamine—Rash—Metformin—polycystic ovary syndrome	0.00159	0.0123	CcSEcCtD
Dihydroergotamine—Dermatitis—Metformin—polycystic ovary syndrome	0.00158	0.0123	CcSEcCtD
Dihydroergotamine—Headache—Metformin—polycystic ovary syndrome	0.00158	0.0122	CcSEcCtD
Dihydroergotamine—Nausea—Metformin—polycystic ovary syndrome	0.00149	0.0116	CcSEcCtD
Dihydroergotamine—CYP3A4—urine—polycystic ovary syndrome	0.00144	0.119	CbGeAlD
Dihydroergotamine—HTR2B—adrenal cortex—polycystic ovary syndrome	0.000769	0.0639	CbGeAlD
Dihydroergotamine—HTR2B—endometrium—polycystic ovary syndrome	0.000687	0.057	CbGeAlD
Dihydroergotamine—HTR2B—uterus—polycystic ovary syndrome	0.000633	0.0526	CbGeAlD
Dihydroergotamine—HTR2B—adipose tissue—polycystic ovary syndrome	0.000619	0.0514	CbGeAlD
Dihydroergotamine—HTR2B—adrenal gland—polycystic ovary syndrome	0.000555	0.0461	CbGeAlD
Dihydroergotamine—HTR1B—endocrine gland—polycystic ovary syndrome	0.000535	0.0444	CbGeAlD
Dihydroergotamine—HTR2B—vagina—polycystic ovary syndrome	0.000515	0.0427	CbGeAlD
Dihydroergotamine—HTR1A—adrenal gland—polycystic ovary syndrome	0.000498	0.0413	CbGeAlD
Dihydroergotamine—HTR1A—endocrine gland—polycystic ovary syndrome	0.000431	0.0358	CbGeAlD
Dihydroergotamine—ADRA2A—endometrium—polycystic ovary syndrome	0.000431	0.0358	CbGeAlD
Dihydroergotamine—ADRA2A—uterus—polycystic ovary syndrome	0.000398	0.033	CbGeAlD
Dihydroergotamine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.00039	0.0324	CbGeAlD
Dihydroergotamine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000389	0.0323	CbGeAlD
Dihydroergotamine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000349	0.029	CbGeAlD
Dihydroergotamine—ABCB1—embryo—polycystic ovary syndrome	0.000328	0.0273	CbGeAlD
Dihydroergotamine—ADRA2A—female gonad—polycystic ovary syndrome	0.000325	0.027	CbGeAlD
Dihydroergotamine—ADRA2A—vagina—polycystic ovary syndrome	0.000323	0.0268	CbGeAlD
Dihydroergotamine—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000302	0.0251	CbGeAlD
Dihydroergotamine—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000269	0.0224	CbGeAlD
Dihydroergotamine—ABCB1—endometrium—polycystic ovary syndrome	0.00024	0.02	CbGeAlD
Dihydroergotamine—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000238	0.0198	CbGeAlD
Dihydroergotamine—ABCB1—uterus—polycystic ovary syndrome	0.000221	0.0184	CbGeAlD
Dihydroergotamine—ABCB1—pituitary gland—polycystic ovary syndrome	0.000218	0.0181	CbGeAlD
Dihydroergotamine—ABCB1—adipose tissue—polycystic ovary syndrome	0.000217	0.018	CbGeAlD
Dihydroergotamine—ABCB1—adrenal gland—polycystic ovary syndrome	0.000194	0.0161	CbGeAlD
Dihydroergotamine—ABCB1—female gonad—polycystic ovary syndrome	0.000181	0.015	CbGeAlD
Dihydroergotamine—ABCB1—vagina—polycystic ovary syndrome	0.00018	0.015	CbGeAlD
Dihydroergotamine—ABCB1—endocrine gland—polycystic ovary syndrome	0.000168	0.014	CbGeAlD
Dihydroergotamine—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	0.00013	0.00016	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	0.00013	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.00013	0.000159	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000129	0.000159	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000129	0.000158	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000128	0.000158	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000128	0.000157	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000127	0.000156	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—STAR—polycystic ovary syndrome	0.000126	0.000155	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.000126	0.000155	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000126	0.000155	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000125	0.000154	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000125	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000125	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000124	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000124	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000124	0.000152	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—SULT2A1—polycystic ovary syndrome	0.000123	0.000152	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000123	0.000151	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000123	0.000151	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000123	0.000151	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000122	0.000149	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FST—polycystic ovary syndrome	0.000121	0.000149	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000121	0.000149	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000121	0.000149	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	0.000121	0.000148	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000121	0.000148	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	0.00012	0.000148	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.00012	0.000147	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—RRM2—polycystic ovary syndrome	0.00012	0.000147	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LHB—polycystic ovary syndrome	0.000118	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000118	0.000145	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000118	0.000145	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000118	0.000145	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000117	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PRL—polycystic ovary syndrome	0.000117	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000117	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000117	0.000143	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PRL—polycystic ovary syndrome	0.000116	0.000143	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000116	0.000142	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—INSR—polycystic ovary syndrome	0.000116	0.000142	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—YAP1—polycystic ovary syndrome	0.000115	0.000142	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000115	0.000141	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IGF1—polycystic ovary syndrome	0.000115	0.000141	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT2—polycystic ovary syndrome	0.000115	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000114	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000114	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PRL—polycystic ovary syndrome	0.000114	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000114	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000113	0.000139	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	0.000113	0.000139	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	0.000113	0.000138	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000112	0.000138	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000112	0.000138	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000112	0.000138	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000111	0.000137	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SCT—polycystic ovary syndrome	0.000111	0.000136	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NAMPT—polycystic ovary syndrome	0.000111	0.000136	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.00011	0.000136	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.00011	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.00011	0.000135	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.00011	0.000135	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP11A1—polycystic ovary syndrome	0.000109	0.000134	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—SERPINE1—polycystic ovary syndrome	0.000109	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000108	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000108	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000108	0.000133	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	0.000107	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000107	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PRL—polycystic ovary syndrome	0.000107	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PGR—polycystic ovary syndrome	0.000107	0.000132	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.000106	0.00013	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000106	0.00013	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000104	0.000128	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKR1C3—polycystic ovary syndrome	0.000103	0.000127	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000103	0.000127	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000103	0.000127	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000103	0.000127	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	0.000103	0.000126	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	0.000103	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000102	0.000126	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP17A1—polycystic ovary syndrome	0.000102	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000102	0.000125	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000102	0.000125	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—GNAS—polycystic ovary syndrome	0.0001	0.000123	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PLAT—polycystic ovary syndrome	9.95e-05	0.000122	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GHRL—polycystic ovary syndrome	9.95e-05	0.000122	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.83e-05	0.000121	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—LHB—polycystic ovary syndrome	9.8e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.75e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NRG1—polycystic ovary syndrome	9.65e-05	0.000119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	9.63e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.59e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	9.58e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NRG1—polycystic ovary syndrome	9.57e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.55e-05	0.000117	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	9.5e-05	0.000117	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ATF1—polycystic ovary syndrome	9.49e-05	0.000117	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GNAS—polycystic ovary syndrome	9.42e-05	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NRG1—polycystic ovary syndrome	9.38e-05	0.000115	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	9.27e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	9.26e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	9.21e-05	0.000113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	9.09e-05	0.000112	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.97e-05	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NRG1—polycystic ovary syndrome	8.81e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TH—polycystic ovary syndrome	8.79e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NGFR—polycystic ovary syndrome	8.76e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—POMC—polycystic ovary syndrome	8.71e-05	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRL—polycystic ovary syndrome	8.68e-05	0.000107	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	8.63e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	8.61e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	8.56e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	8.53e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	8.5e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	8.41e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	8.37e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	8.27e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IRS2—polycystic ovary syndrome	8.26e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.24e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IRS2—polycystic ovary syndrome	8.2e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	8.16e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—LEP—polycystic ovary syndrome	8.09e-05	9.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	8.04e-05	9.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IRS2—polycystic ovary syndrome	8.03e-05	9.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—LEP—polycystic ovary syndrome	8.03e-05	9.86e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	7.97e-05	9.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—LEP—polycystic ovary syndrome	7.86e-05	9.66e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	7.82e-05	9.61e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	7.82e-05	9.61e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	7.78e-05	9.57e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	7.66e-05	9.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GNAS—polycystic ovary syndrome	7.64e-05	9.39e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	7.56e-05	9.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IRS2—polycystic ovary syndrome	7.54e-05	9.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	7.53e-05	9.26e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	7.49e-05	9.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	7.46e-05	9.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—LEP—polycystic ovary syndrome	7.38e-05	9.07e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	7.28e-05	8.94e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.28e-05	8.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	7.24e-05	8.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IRS1—polycystic ovary syndrome	7.21e-05	8.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	7.18e-05	8.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IRS1—polycystic ovary syndrome	7.16e-05	8.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NRG1—polycystic ovary syndrome	7.14e-05	8.78e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	7.14e-05	8.77e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	7.03e-05	8.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IRS1—polycystic ovary syndrome	7.01e-05	8.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—POMC—polycystic ovary syndrome	6.95e-05	8.54e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	6.94e-05	8.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—INS—polycystic ovary syndrome	6.91e-05	8.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—POMC—polycystic ovary syndrome	6.89e-05	8.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	6.89e-05	8.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—INS—polycystic ovary syndrome	6.86e-05	8.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	6.84e-05	8.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	6.84e-05	8.4e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	6.82e-05	8.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—POMC—polycystic ovary syndrome	6.75e-05	8.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—INS—polycystic ovary syndrome	6.71e-05	8.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IGF1—polycystic ovary syndrome	6.68e-05	8.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT2—polycystic ovary syndrome	6.68e-05	8.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IGF1—polycystic ovary syndrome	6.63e-05	8.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT2—polycystic ovary syndrome	6.63e-05	8.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	6.62e-05	8.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	6.59e-05	8.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.58e-05	8.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	6.49e-05	7.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	6.49e-05	7.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	6.48e-05	7.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.47e-05	7.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.35e-05	7.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	6.34e-05	7.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	6.31e-05	7.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.3e-05	7.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.17e-05	7.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	6.12e-05	7.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	6.1e-05	7.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	6.1e-05	7.49e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TH—polycystic ovary syndrome	6.08e-05	7.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	6.04e-05	7.43e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	6.04e-05	7.42e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	6e-05	7.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	5.99e-05	7.36e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	5.92e-05	7.27e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	5.9e-05	7.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.79e-05	7.12e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.72e-05	7.03e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	5.71e-05	7.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	5.61e-05	6.9e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	5.56e-05	6.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	5.34e-05	6.56e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	5.26e-05	6.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	5.14e-05	6.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	5.11e-05	6.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	5.11e-05	6.28e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	5.09e-05	6.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	5.07e-05	6.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	4.97e-05	6.1e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	4.96e-05	6.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	4.95e-05	6.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	4.94e-05	6.07e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.91e-05	6.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	4.9e-05	6.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	4.83e-05	5.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	4.81e-05	5.91e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	4.81e-05	5.91e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	4.73e-05	5.81e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	4.72e-05	5.8e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	4.71e-05	5.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.7e-05	5.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	4.66e-05	5.73e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	4.66e-05	5.72e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	4.48e-05	5.51e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	4.4e-05	5.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.37e-05	5.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.33e-05	5.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	4.33e-05	5.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.24e-05	5.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	4.2e-05	5.16e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	4.18e-05	5.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	4.04e-05	4.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	4.02e-05	4.94e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.98e-05	4.9e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.89e-05	4.78e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.89e-05	4.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.78e-05	4.65e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.75e-05	4.6e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.69e-05	4.54e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.64e-05	4.48e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	3.43e-05	4.21e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	3.39e-05	4.16e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—polycystic ovary syndrome	3.34e-05	4.11e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—INS—polycystic ovary syndrome	3.32e-05	4.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.23e-05	3.97e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	3.06e-05	3.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	3.02e-05	3.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	3e-05	3.68e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.97e-05	3.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	2.93e-05	3.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.91e-05	3.58e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.76e-05	3.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	2.76e-05	3.39e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.58e-05	3.16e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.54e-05	3.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	2.23e-05	2.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	2.09e-05	2.57e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	2.06e-05	2.53e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—INS—polycystic ovary syndrome	2.05e-05	2.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.76e-05	2.16e-05	CbGpPWpGaD
